20
Hagiwara H., Sakamoto S., Katsumata T., Katayama Y. Acute disseminated
encephalomyelitis developed after Mycoplasma pneumoniae infection complicating
subclinical measles infection // Intern. Med.
–
2009.
–
Vol. 48, № 6. –
P. 479-483.
Hanafusa N., Kondo Y., Suzuki M. et al. Double filtration plasmapheresis can
decrease factor XIII activity // Ther. Apher. Dial.
–
2007.
–
Vol.11, № 3. –
P. 165-170.
Hao Q., Saida T., Yoshino H. et al. Anti-GalNAc-GD1a antibody-associated Guillain-
Barr
é
syndrome with a predominantly distal weakness without cranial nerve impairment
and sensory disturbance // Ann. Neurol.
–
1999.
–
Vol. 45, № 6. –
P. 758-768.
Hashimoto H. Microscopic polyangiitis in systemic sclerosis // Int. J. Reumatol.
–
2010, 2010: 148528.
Haupt W.F. Recent advances of therapeutic apheresis in Guillain-Barr
é
syndrome //
Ther. Apher.
–
2000.
–
Vol. 4, № 4. –
P. 271-274.
Hughes R.A., Wijdicks E.F., Barohn R. et al. Practice parameter: immunotherapy for
Guillain-Barr
é
syndrome: report of the Quality Standards Subcommittee of the American
Academy of Neurology // Neurology.
–
2003.
–
Vol. 61, № 6. –
P. 736-740.
Hughes R.A., Swan A.V., Rapha
ё
l J.C. et al. Immunotherapy for Guillain-Barr
é
syndrome: a systematic review // Brain.
–
2007.
–
Vol. 130, Pt 9.
–
P. 2245-2257.
Hughes R.A.C. Give or take? Intravenous immunoglobulin or plasma exchange for
Guillain-Barr
é
syndrome // Crit. Care.
–
2011.
–
Vol. 15, № 4. –
P. 174.
Hund E.F., Fogel W., Krieger D. et al. Critical illness polyneuropathy: clinical
findings and outcomes of a frequent cause of neuromuscular weaning failure // Crit. Car
Med.
–
1996.
–
Vol.24, № 8. –
P. 1328-1333.
Iodice V., Kimpinski K., Vernini S. et al. Efficacy of immunotherapy in serpositive
and seronegative putative autoimmune autonomic gangliopathy // Neurology.
–
2009.
–
Vol
. 72, № 23. –
P. 2002-2008.
Jaben E.A., Pulido J.S., Pittick S. et al. The potential role of plasma exchange as
treatment for bilateral diffuse uveal melanocytic proliferation: a report of two cases // J.
Clin. Apher.
–
2011.
–
Vol. 26, № 6. –
P. 356-361.
Karim S., Majithia V.
Devic’s syndrome as initial presentation of systemic lupus
erythematosus // Am. J. Med. Sci.
–
2009.
–
Vol. 338, № 3. –
P. 245-247.
Kaynar L., Altuntas F., Aydoglu I. et al. Therapeutic plasma exchange in patients
with neurologic diseases: retrospective multicenter study // Transfus. Apher. Sci.
–
2008.
–
Vol. 38, № 2. –
P. 109-115.
Khatri B.O., McQuillen M.P., Hoffman R.G. Plasma exchange in chronic progressive
multiple sclerosis. A long term study // Neurology. - 1991. -
Vol. 41, №
4. - P. 409-414.
Khatri B.O., Man S., Giovannoni G. et al. Effect of plasma exchange in accelerating
natalizumab clearance and restoring leukocyte function // Neurology.
–
2009.
–
Vol. 72,
№ 5. –
P. 402-409.
Kincaid J.C. Apheresis in treatment of the inflammatory demyelinating peripheral
neuropathies // Ther. Apher. Dial.
–
2002.
–
Vol. 6, № 1. –
P. 53-56.
21
Koehler P.J., Kondstaal J. Lethal hypersensitivity myocarditis associated with the
use of intravenous gammaglobulin for Guillain-
Barré syndrome, in comb
ination with
phenitoin // Neurology.
–
1996.
–
Vol. 243, № 4. –
P. 366-367.
K
öhler W., Bucka C., Klingel R.
A randomized and controlled study comparing
immunoadsorption and plasma exchange in myasthenic crisis // J. Clin. Apher..
–
2011.
–
Vol. 26, № 6. –
P. 347-355.
Konishi T. [Plasmapheresis in patients with myasthenia gravis] // Nippon Rinsho.
–
2008.
–
Vol. 66, № 6. –
P. 1165-1171.
Kornberg A.J., Pertronk A. Chronic motor neuropathies: diagnosis, therapy, and
pathogenesis // Ann. Neurol. - 1995. - Vol. 37, Suppl. 1. -S43-50.
Körner H., Riminton D.S., Stickland D.H. et al.
Critical points of tumor necrosis
factor action in central nervous system autoimmune inflammation defined by gene
targeting // J. Exp. Med. - 1997. -
Vol. 186, № 9.
- P. - 1585-1590.
Keegan M., Pineda A.A., McClelland R.L. et al. Plasma exchange for severe attacks
of CNS demyelination: predictors of response // Neurology.
–
2002.
–
Vol. 58, № 1. –
P.
143-146.
Landtblom A.M., Lindval B., Ledin T., Berlin G. A case report of plasmapheresis
treatment in a patient with paraneoplastic cerebellar degeneration and high anti -yo
antibody titres // Ther. Apher. Dial.
–
2008.
–
Vol. 12, № 1. –
P. 82-85.
Latov N. Pathogenesis and therapy of neuropathies associated with monoclonal
gammapathy // Ann. Neurol. - 1995. - Vol. 37, Suppl. 1. - P. S32-42.
Levis R.A., Selwa J.F., Lisak R.P. Myasthenia gravis: immunological mechanisms
and immunotherapy // Ann. Neurol. - 1995. - Vol. 37, Suppl. 1. - P. S51-S62.
Leys K., Lang B., Johnston I., Newsom-Davis J. Calcium channel autoantibodies in
the Lambert-Eaton myasthenic syndrome // Ann. Neurol. - 1991. -
Vol. 29, № 3.
- P.
307-314.
Lin C.H., Jeng J.S., Yip P.K. Plasmapheresis in acute disseminated
encephalomyelitis // J. Clin. Apher.
–
2004.
–
Vol. 19, № 3. –
P. 154-159.
Lindstrom J.M., Seybold M.E., Lenon V.A. et al. Antibody to acetylcholine receptor
in myastenia gravis: prevalence, clinical correlates, and diagnostic value // Neurology. -
1998. -
Vol. 51, № 4.
- P. 933.
Liu J.F., Wang W.X., Xue J. et al. Comparing the autoantibody levels and clinical
efficacy of double plasmapheresis, immunoadsorption, and intravenous immunoglobulin
for the treatment of late-onset myasthenia gravis //Ther. Apher. Dial.
–
2010.
–
Vol. 14,
№ 2. –
P. 153-160.
Llufriu S., Castillo J., Blanco Y. et al. Plasma exchange for acute attacks of CNS
demyelination: predictors of improvement at 6 months // Neurology.
–
2009.
–
Vol. 73,
№ 12. –
P. 949-953.
Lo Y.L. Clinical and immunological spectrum of the Miller Fisher syndrome // Muscle
Nerve.
–
2007.
–
Vol. 36, № 5. –
P.615-627.